We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

HAIN:NASDAQThe Hain Celestial Group, Inc. Analysis

Data as of 2026-04-07 - not real-time

$0.81

Latest Price

8/10Risk

Risk Level: High

Executive Summary

The Hain Celestial Group is trading at a deep discount to its book and sales, with a price‑to‑book of 0.22 and price‑to‑sales of 0.05, while the forward P/E sits around 5.5. However, the company is reporting a steep negative profit margin of -36%, a ROE of -95%, and a debt‑to‑equity ratio exceeding 200%, indicating significant financial strain. Technically, the stock is above its 20‑day SMA but below the 50‑day and 200‑day averages, and the MACD histogram is only modestly bullish, suggesting limited upside momentum. Recent news shows a Barclays downgrade to Underweight and a 5.9% intraday drop, reinforcing short‑term bearish sentiment, even as analyst price targets imply up to 75% upside.
The market’s “Extreme Greed” sentiment contrasts sharply with the company’s high 30‑day volatility (>100%) and a historic max drawdown of nearly 85%. Given the increasing volume, the stock may find support near $0.58, but the current resistance around $0.87 looms. Investors must weigh the substantial valuation discount against the deteriorating earnings profile and heavy leverage when deciding on exposure.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Barclays downgrade to Underweight
  • Current price below 50‑day SMA indicating bearish trend
  • High volatility and recent sharp price decline

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Significant valuation discount to book and sales
  • Analyst price targets suggesting upside potential
  • Continued earnings losses and high leverage

Long Term

> 3 years
Positive
Model confidence: 5/10

Key Factors

  • Deep undervaluation relative to assets
  • Long‑term growth of the natural and organic food market
  • Potential for balance‑sheet restructuring and turnaround

Key Metrics & Analysis

Financial Health

Revenue Growth-6.70%
Profit Margin-36.12%
P/E Ratio5.5
ROE-95.83%
ROA1.65%
Debt/Equity232.07
P/B Ratio0.2
Op. Cash Flow$30.5M
Free Cash Flow$48.5M

Technical Analysis

TrendBearish
RSI57.1
Support$0.58
Resistance$0.87
MA 20$0.67
MA 50$0.85
MA 200$1.30
MACDBullish
VolumeIncreasing
Fear & Greed Index77.54

Valuation

Target Price$1.42
Upside/Downside75.41%
GradeUndervalued
TypeValue

Risk Assessment

Beta1.10
Volatility101.23%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.